Cite
Performance Characteristics of DOAC-Remove for Neutralization of the Effects of Apixaban and Rivaroxaban in Lupus Anticoagulant Assays.
MLA
Skaugen, John M., et al. “Performance Characteristics of DOAC-Remove for Neutralization of the Effects of Apixaban and Rivaroxaban in Lupus Anticoagulant Assays.” American Journal of Clinical Pathology, vol. 157, no. 3, Mar. 2022, pp. 457–69. EBSCOhost, https://doi.org/10.1093/ajcp/aqab149.
APA
Skaugen, J. M., Sayre, C., Hassett, A. C., Chibisov, I., Bontempo, F., Meyer, M. P., & Seheult, J. N. (2022). Performance Characteristics of DOAC-Remove for Neutralization of the Effects of Apixaban and Rivaroxaban in Lupus Anticoagulant Assays. American Journal of Clinical Pathology, 157(3), 457–469. https://doi.org/10.1093/ajcp/aqab149
Chicago
Skaugen, John M, Christine Sayre, Andrea Cortese Hassett, Irina Chibisov, Franklin Bontempo, Michael P Meyer, and Jansen N Seheult. 2022. “Performance Characteristics of DOAC-Remove for Neutralization of the Effects of Apixaban and Rivaroxaban in Lupus Anticoagulant Assays.” American Journal of Clinical Pathology 157 (3): 457–69. doi:10.1093/ajcp/aqab149.